BioMed Research International

Special Issue on
Molecular Markers in the Diagnosis and Treatment of Cancer 2016

CALL FOR PAPERS

It is with great pleasure that we announce the second issue of Molecular Markers in the Diagnosis and Treatment of Cancer. The inaugural issue drew high interest and attention with close to 60 manuscript submissions, resulting in the publication of 22 of them, creating a compilation of highly-informative original investigations and reviews of the subject from different perspectives. Due to the success of the first issue published in 2015, a second issue is going to be published in 2016 and we are looking forward to the publication of another successful special issue on this highly influential and timely subject.

Genetic alterations have been identified in many disease processes, including a variety of neoplasms. As more of these alterations are being discovered, their significance in some diseases remains obscure, while they have become diagnostic genetic signatures for others. In addition, increasingly growing numbers of these alterations are now the subject of targeted therapies. They can also provide significant prognostic and predictive to treatment information, further blurring the boundaries between diagnosis and treatment, as well as basic and clinical sciences. Of paramount importance are the developments in our understanding of genetic aspects of disease and the explosion of knowledge in molecular biology. The latter has been translated into clinical application in the form of molecular diagnostics, involving high technology testing. Altogether, we have a better understanding of how such alterations operate in the process of oncogenesis, which in turn helps us to better diagnose and treat neoplasms based on these alterations. O6-methylguanine DNA methyltransferase (MGMT) gene methylation status in glioblastoma and response to alkylating agents, c-kit mutations in gastrointestinal stromal tumor (GIST) and ALK gene rearrangements in ALK-positive anaplastic large cell lymphoma or neuroblastoma, and gefitinib targeting epidermal growth factor receptor (EGFR) in non-small cell lung cancer are a few examples of how genetic alterations, identified by molecular diagnostic testing, can impact treatment.

As such, we are particularly interested in manuscripts that report technical, basic, and clinical research, molecular biology, diagnostic and therapeutic aspects of neoplasia, and clinical trials involving these topics, as well as review papers on any of these subjects. The topics are not limited to a particular organ, system, type of neoplasia, or specific age; however, the main purpose is to compile an issue composed of manuscripts that emphasize the molecular markers in such aspects of neoplasia in an attempt to provide the reader with an up-to-date source of current research on the state of molecular markers.

Potential topics include, but are not limited to:

- Molecular diagnostic techniques
- Oncogenesis
- Diagnostic markers of cancer
- Prognostic and predictive markers of cancer
- Molecularly targeted therapies and drug discovery
- Personalized medicine and molecular markers

Authors can submit their manuscripts via the Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/oncology/mdt16/.

Lead Guest Editor
Murat Gokden, University of Arkansas for Medical Sciences, Little Rock, USA
mgokden@uams.edu

Guest Editors
Konstantinos Arnaoutakis, University of Arkansas for Medical Sciences, Little Rock, USA
karnaoutakis@uams.edu

Antonio Ruggiero, Catholic University of Rome, Rome, Italy
ruggiero@rm.unicatt.it

Manuscript Due
Friday, 10 June 2016

First Round of Reviews
Friday, 2 September 2016

Publication Date
Friday, 28 October 2016